Advances in Pharmacology and Therapeutics Journal
Shahid Sadoughi University of Medical Sciences, Yazd, Iran

SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES

Editorial Article

The AI Revolution in Drug Discovery: From Computational Innovation to Clinical Translation

Running Title: Artificial Intelligence in Drug Discovery

Mohsen Zabihi[1*]

[1] Traditional Pharmacy and Pharmaceutical Science Research Center, and Department of Toxicology and Pharmacology, Faculty of Pharmacy, Shahid Sadoughi University of Medical Cciences, Yazd, Iran.

ARTICLEINFO

Received: 07/21/2026

Accepted: 07/22/2026

***Corresponding author**
Traditional Pharmacy and Pharmaceutical Science Research Center, and Department of Toxicology and Pharmacology, Faculty of Pharmacy, Shahid Sadoughi University of Medical Cciences, Yazd, Iran.

Tel: +98-9131536813

E-mail
mzabihi1000@gmail.com

ORCID ID
0000-0002-8929-3684

Abstract

Artificial intelligence (AI) has rapidly evolved from a computational research tool into a major driver of innovation across the pharmaceutical development pipeline. Advances in deep learning, foundation models, protein structure prediction, and generative molecular design have accelerated target identification, compound optimization, toxicity prediction, and biomarker discovery. These developments have substantially reduced the time required to generate and prioritize therapeutic hypotheses.

Despite this remarkable progress, the translation of computational predictions into clinically effective medicines remains challenging. Drug development continues to be limited by biological complexity, patient heterogeneity, incomplete datasets, and the need for rigorous experimental and clinical validation. AI can improve decision-making, but it cannot replace the biological evidence required for regulatory approval or patient care.

This editorial discusses the evolving role of AI in modern drug discovery while highlighting the importance of explainable algorithms, high-quality biomedical data, real-world evidence, and interdisciplinary collaboration. Rather than viewing AI as a replacement for scientists, clinicians, or pharmacologists, it should be considered a powerful partner that enhances scientific reasoning and accelerates translational research.

The future of pharmaceutical innovation will depend on integrating computational intelligence with experimental pharmacology, clinical medicine, and regulatory science. Responsible implementation—not computational sophistication alone—will determine whether AI ultimately delivers safer, more effective, and more personalized therapies for patients.

Keywords: Artificial Intelligence; Drug Discovery; Machine Learning; Generative AI; Precision Medicine; Drug Development.

Citation: Zabihi M. The AI Revolution in Drug Discovery: From Computational Innovation to Clinical Translation. Adv Pharmacol Ther J. 2026;6(1): 1-10.

Introduction

Artificial intelligence has become one of the most influential technologies shaping modern biomedical research. What was once regarded as a computational support tool is now transforming nearly every stage of drug discovery—from identifying therapeutic targets to designing novel molecules and optimizing clinical development strategies. The combination of rapidly expanding biomedical datasets and increasingly sophisticated machine-learning algorithms has created opportunities that were difficult to imagine only a decade ago (1-4).

Among the most important milestones has been the development of deep-learning models capable of predicting protein structures with near-experimental accuracy. Together with recent advances in generative AI and multimodal foundation models, these technologies have expanded researchers' ability to explore chemical and biological space far beyond the limits of traditional computational methods (1, 2, 5).

These achievements have generated understandable enthusiasm throughout academia and the pharmaceutical industry. AI-driven platforms can screen millions of compounds within hours, predict molecular interactions, identify potential biomarkers, and support the discovery of novel therapeutic candidates. Such capabilities are particularly valuable at a time when drug development remains expensive, time-consuming, and associated with high attrition rates (3, 6).

Yet technological progress should not be confused with clinical success. History offers many examples of innovations that transformed laboratory research but required years of careful validation before producing meaningful improvements in patient care. Artificial intelligence is unlikely to be an exception. While AI can greatly enhance the efficiency of hypothesis generation and decision-making, it does not eliminate the biological uncertainty that characterizes human disease.

Drug discovery is fundamentally different from data analysis. A computational model may accurately predict molecular interactions, but therapeutic success ultimately depends on complex biological processes, including pharmacokinetics, pharmacodynamics, immune regulation, genetic diversity, disease heterogeneity, and long-term safety. These factors cannot yet be fully captured by even the most advanced algorithms (7, 8). For this reason, the future of AI in pharmaceutical science should not be viewed as a competition between human expertise and machine intelligence. Instead, it should be seen as a collaborative model in which computational methods accelerate discovery while experimental science and clinical research provide the evidence required to translate predictions into effective medicines.

This editorial explores the opportunities and current limitations of AI-assisted drug discovery and argues that the greatest impact of artificial intelligence will be achieved not through autonomous decision-making, but through its thoughtful integration into evidence-based biomedical research.

Artificial Intelligence Is Reshaping Drug Discovery—But Not Drug Development

Artificial intelligence has already transformed the earliest phases of pharmaceutical research. Machine-learning algorithms can now integrate genomic, proteomic, chemical, imaging, and clinical data to

  DOI: https://doi.org/10.18502/aptj.v6i1.?????

identify therapeutic targets, prioritize drug candidates, and predict molecular properties with unprecedented speed. Tasks that previously required months of laboratory screening can often be completed computationally within days, allowing researchers to focus experimental efforts on the most promising candidates (3–5).

Perhaps the most striking impact of AI has been its ability to navigate the enormous chemical space available for drug discovery. Traditional medicinal chemistry is constrained by time, cost, and the practical limitations of synthesizing and testing compounds. In contrast, generative AI models can rapidly propose novel molecular structures that satisfy predefined pharmacological or physicochemical properties, expanding opportunities for lead optimization beyond conventional approaches (5, 9).

The influence of AI extends well beyond molecular design. Machine-learning models are increasingly used to predict drug–target interactions, estimate absorption and metabolic properties, identify toxicity signals, and support biomarker discovery. Collectively, these applications improve the quality of early decision-making and may reduce the number of compounds that fail during later stages of development (3, 10).

Nevertheless, computational efficiency should not be mistaken for clinical readiness. Drug discovery and drug development are often discussed as if they represent a single continuous process. In reality, they address fundamentally different scientific questions. Drug discovery seeks to identify promising therapeutic candidates, whereas drug development determines whether those candidates are sufficiently safe and effective for use in humans. AI has clearly accelerated the first objective; its impact on the second remains far more limited.

This distinction reflects the inherent complexity of human biology. A compound predicted to bind a molecular target with high affinity may ultimately fail because of inadequate pharmacokinetics, unexpected toxicity, poor tissue distribution, immune-mediated adverse effects, or insufficient clinical efficacy. These factors emerge from interactions across multiple biological systems and remain difficult to predict using computational models alone (7, 11).

Recent advances in protein structure prediction illustrate this point well. Systems such as AlphaFold have fundamentally changed structural biology by providing highly accurate structural information for millions of proteins. Yet knowing the three-dimensional structure of a target does not automatically reveal whether modulating that target will improve patient outcomes. Disease mechanisms are dynamic rather than static, and therapeutic success depends on networks of biological interactions that extend well beyond individual proteins (1, 2).

Another important limitation concerns the quality of the data used to train AI models. Machine-learning algorithms learn from existing information rather than from biological principles. If training datasets are incomplete, unbalanced, or biased toward particular populations, predictions may perform well during internal validation but fail when applied to broader clinical settings. This challenge is particularly relevant in precision medicine, where

genetic diversity, environmental exposure, and healthcare inequalities can substantially influence treatment response (12, 13).

These limitations do not diminish the value of artificial intelligence. Instead, they redefine its role. Rather than replacing experimental pharmacology, AI should be viewed as a sophisticated hypothesis-generation engine. Its greatest contribution lies in identifying opportunities that warrant biological investigation, narrowing an otherwise overwhelming search space, and enabling scientists to allocate laboratory resources more efficiently. Experimental validation remains indispensable because it determines whether computational predictions reflect biological reality.

In this sense, the relationship between AI and experimental science is becoming increasingly iterative. Algorithms generate hypotheses, laboratory experiments test those hypotheses, and the resulting data are then used to refine subsequent computational models. This continuous feedback loop is likely to become a defining feature of next-generation drug discovery, creating a learning system in which computational and experimental sciences evolve together rather than independently.

Such a perspective also encourages a more realistic view of AI's future. The most meaningful advances are unlikely to arise from fully autonomous drug discovery platforms. Instead, progress will depend on collaborative systems that combine computational intelligence with human expertise, biological insight, and rigorous experimental validation. The objective is not to automate scientific judgment but to strengthen it.

From Algorithms to Medicines: The Challenge of Clinical Translation

The growing influence of artificial intelligence has shifted the focus of pharmaceutical research from data generation to knowledge generation. Modern AI systems can integrate diverse biomedical datasets, recognize subtle biological patterns, and produce predictions that would be difficult—or even impossible—for humans to generate unaided. Yet the true value of these predictions depends on a single question: Do they improve patient outcomes?

This question defines the gap between computational discovery and clinical translation. Many AI models demonstrate outstanding performance during internal validation. However, performance metrics such as accuracy or the area under the receiver operating characteristic curve do not necessarily predict clinical usefulness. A model that performs exceptionally well in a controlled dataset may lose reliability when applied to patients from different healthcare systems, ethnic backgrounds, or disease populations (12, 14).

One explanation is that biological systems continuously adapt. Diseases evolve over time, patients differ in their genetic makeup and environmental exposures, and therapeutic responses are influenced by factors that extend far beyond molecular interactions. Consequently, successful drug development requires more than identifying a promising target or designing an attractive molecule; it requires demonstrating that a therapeutic intervention produces meaningful clinical benefit under real-world conditions. For this reason, experimental validation remains the cornerstone of

  DOI: https://doi.org/10.18502/aptj.v6i1.?????

translational research. AI can prioritize hypotheses, but laboratory studies determine whether those hypotheses are biologically plausible. Cellular assays, organoids, animal models, and increasingly sophisticated human-based experimental platforms continue to provide essential evidence before candidate drugs enter clinical testing (15).

Clinical trials represent an equally indispensable step. Randomized controlled trials remain the most reliable method for establishing efficacy and safety because they minimize bias and allow causal inference. Although AI may improve trial design by identifying eligible participants, predicting recruitment challenges, or selecting biomarkers, it cannot replace the evidence generated through prospective clinical investigation (16).

Beyond clinical trials**, real-world evidence (RWE)** is becoming increasingly important in evaluating the long-term performance of medicines. Electronic health records, disease registries, digital health technologies, and patient-reported outcomes provide valuable information about effectiveness and safety in routine clinical practice. When analyzed appropriately, these data complement randomized trials by revealing how treatments perform in broader and more diverse patient populations (17, 18).

Artificial intelligence is particularly well suited to extracting clinically relevant insights from these complex datasets. Machine-learning algorithms can identify unexpected safety signals, characterize treatment-response patterns, and support post-marketing surveillance at a scale that would be difficult to achieve using conventional statistical approaches. As regulatory agencies increasingly recognize the value of real-world evidence, AI is expected to play an expanding role throughout the entire life cycle of medicinal products (18, 19).

However, this opportunity also introduces new responsibilities. Transparency has become one of the defining challenges of biomedical AI. Many advanced deep-learning models achieve impressive predictive performance while offering limited insight into the reasoning behind their predictions. In drug discovery, where algorithmic outputs may influence major scientific and financial decisions, this lack of interpretability can reduce confidence among researchers, clinicians, regulators, and patients.

Accordingly, the development of **explainable artificial intelligence (XAI)** has emerged as a priority. Rather than functioning as opaque "black boxes," future AI systems should provide interpretable evidence that helps researchers understand why a prediction was made, which biological features were influential, and where uncertainty remains. Explainability is not simply a technical improvement—it is essential for scientific credibility and regulatory acceptance (20).

Another challenge concerns data quality. AI systems inherit the strengths and weaknesses of the datasets on which they are trained. Missing information, inconsistent annotations, underrepresentation of certain populations, and historical biases may all reduce model reliability. Consequently, improving AI performance in drug discovery depends as much on better biomedical data as on more sophisticated algorithms (13, 21).

Looking ahead, the most successful AI platforms are unlikely to be those that operate independently.

Instead, they will be those that integrate seamlessly with experimental pharmacology, clinical expertise, and regulatory science. Progress will depend on continuous interaction between computational prediction, biological validation, and clinical observation—a process in which every stage informs and strengthens the next.

Ultimately, AI should be viewed not as a shortcut through drug development, but as a catalyst that makes the scientific process more efficient, more informed, and more capable of addressing complex biomedical questions.

Building a Trustworthy AI Ecosystem for Drug Discovery

The future of artificial intelligence in drug discovery will depend less on developing increasingly sophisticated algorithms and more on building systems that researchers, clinicians, regulators, and patients can trust. Scientific credibility is earned through transparency, reproducibility, and rigorous validation—not simply through computational performance.

In recent years, AI has evolved from a collection of specialized machine-learning models to large multimodal foundation models capable of integrating chemical structures, genomic profiles, medical images, electronic health records, and scientific literature. These advances have created opportunities to study diseases as interconnected biological systems rather than isolated molecular events (22). Such integration is particularly attractive for complex disorders, including cancer, neurodegenerative diseases, autoimmune conditions, and rare genetic disorders, where multiple biological pathways contribute to disease progression.

However, larger models do not automatically produce better science. Increasing model complexity often reduces interpretability and may introduce new sources of uncertainty. Highly sophisticated algorithms can generate convincing predictions while providing little explanation of how those conclusions were reached. In biomedical research, this is a significant limitation because scientific decisions must be justified by biological evidence rather than computational confidence alone.

This is where **explainable artificial intelligence (XAI)** becomes essential. Explainability allows researchers to identify the molecular features, biological pathways, or clinical variables that contribute most strongly to a model's predictions. Such information not only increases confidence in computational findings but also generates hypotheses that can be tested experimentally. In this context, explainability serves as a bridge between data science and biological understanding rather than simply an additional computational feature (20).

Trust also depends on fairness. Biomedical datasets are rarely perfect representations of the populations that ultimately receive medical care. Differences in ethnicity, age, sex, socioeconomic status, healthcare access, and disease prevalence may all influence model performance. Algorithms trained on limited datasets can unintentionally reinforce existing healthcare disparities if applied without appropriate external validation (13, 21).

Addressing these concerns requires international collaboration and broader data diversity. Future AI models should be developed and validated using datasets collected across multiple healthcare systems

  DOI: https://doi.org/10.18502/aptj.v6i1.?????

and geographic regions. External validation should become a routine expectation rather than an optional step, particularly for models intended to support clinical decision-making.

Another important development is federated learning, which enables institutions to train shared AI models without transferring individual patient data outside their local environments. Instead of centralizing sensitive healthcare information, participating institutions exchange model parameters while retaining control of their own datasets. This strategy offers an effective balance between collaborative research and patient privacy, making it particularly attractive for multinational biomedical studies (23).

Equally important is the emergence of **continuous-learning healthcare systems.** Traditionally, evidence generation has followed a linear pathway in which discoveries progress from laboratory research to clinical trials and eventually to clinical practice. AI has the potential to create a more dynamic model in which clinical experience continuously informs future research.

For example, post-marketing safety data, electronic health records, wearable devices, and patient-reported outcomes can be incorporated into learning systems that identify emerging therapeutic patterns and generate new research questions. Rather than ending when a drug receives regulatory approval, knowledge generation can continue throughout its entire clinical life cycle (17,19).

Regulatory science will play a pivotal role in supporting this transition. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have acknowledged that AI will increasingly influence every stage of medicinal product development, from target identification to post-marketing surveillance. Their current guidance emphasizes transparency, data quality, human oversight, and ongoing performance monitoring as essential requirements for trustworthy AI systems (19, 24).

These evolving frameworks reflect an important principle: successful AI implementation should be judged not by technological novelty, but by its ability to improve scientific rigor and patient care.

Ultimately, the future of drug discovery is unlikely to be defined by autonomous algorithms replacing researchers. Instead, it will depend on partnerships in which computational models generate hypotheses, experimental scientists test biological mechanisms, clinicians evaluate therapeutic relevance, and regulators ensure that innovations meet appropriate standards of safety and effectiveness.

Viewed from this perspective, artificial intelligence is not the destination of pharmaceutical innovation. It is an enabling technology that, when integrated responsibly, has the potential to make biomedical research more efficient, more reproducible, and more responsive to the needs of patients.

Looking Ahead: From Artificial Intelligence to Intelligent Drug Discovery

Artificial intelligence is often presented as the defining technology of the next generation of pharmaceutical research. While this expectation is justified, the future of drug discovery will depend not simply on more powerful algorithms but on how effectively computational intelligence is integrated into biological science, clinical medicine, and regulatory practice.

The pharmaceutical industry is already moving beyond isolated AI applications toward integrated discovery platforms. Advances in multimodal foundation models now allow researchers to combine molecular structures, omics data, medical imaging, clinical records, and scientific literature within a single analytical framework. Rather than studying individual biological components in isolation, these systems seek to understand disease as a dynamic network of interacting pathways (22, 25).

This systems-level perspective may prove particularly valuable for diseases that have resisted conventional drug development strategies. Neurodegenerative disorders, autoimmune diseases, metabolic syndromes, and many forms of cancer arise from complex biological interactions rather than a single molecular abnormality. AI offers an opportunity to explore this complexity more systematically, identifying therapeutic opportunities that might otherwise remain hidden.

At the same time, expectations should remain realistic. Drug discovery has never been limited solely by the ability to analyze data. It is constrained by the complexity of biology itself. Human diseases evolve over time, therapeutic responses vary among individuals, and many biological mechanisms remain only partially understood. Artificial intelligence can reduce uncertainty, but it cannot eliminate it.

This distinction is important because unrealistic expectations may ultimately undermine confidence in the technology. As with previous scientific innovations, the impact of AI should be evaluated by measurable improvements in research productivity, therapeutic innovation, and patient outcomes—not by the sophistication of the algorithms themselves.

For this reason, future progress will require a stronger culture of interdisciplinary collaboration. Computational scientists, medicinal chemists, pharmacologists, clinicians, statisticians, and regulatory experts each contribute different forms of expertise. AI performs best when these perspectives are integrated rather than separated.

Education will also become increasingly important. Tomorrow's biomedical researchers will need to understand not only molecular biology and pharmacology but also the principles underlying machine learning, data governance, model validation, and algorithmic bias. Likewise, data scientists working in healthcare must appreciate the biological and clinical context in which their models are expected to operate.

Equally important is the continued evolution of regulatory science. Regulatory agencies are progressively developing frameworks for evaluating AI-assisted technologies, emphasizing transparency, reproducibility, cybersecurity, and continuous post-deployment monitoring (19, 24). These efforts recognize that trustworthy AI requires ongoing evaluation rather than one-time validation. Perhaps the greatest contribution of artificial intelligence will be a change in how drug discovery itself is conducted.

Traditionally, pharmaceutical research has followed a sequential workflow in which each stage begins only after the previous stage has been completed. AI enables a more iterative model in which

  DOI: https://doi.org/10.18502/aptj.v6i1.?????

computational prediction, laboratory experimentation, clinical investigation, and real-world evidence continuously inform one another. Such an adaptive framework has the potential to shorten development timelines while improving scientific decision-making throughout the drug development process.

Importantly, this transformation should remain firmly patient-centered. The ultimate purpose of AI is not to produce increasingly complex computational models or larger datasets. Its success should be measured by whether it helps deliver medicines that are safer, more effective, more affordable, and accessible to the patients who need them most.

In this respect, artificial intelligence should be viewed neither as a replacement for scientific expertise nor as an independent decision-maker. It is best understood as an advanced research partner—one capable of extending human analytical capacity while leaving biological interpretation, ethical judgment, and clinical responsibility in human hands.

Conclusion

Artificial intelligence has already begun to reshape the landscape of drug discovery. Its influence is evident in target identification, molecular design, toxicity prediction, biomarker discovery, and clinical data analysis. These advances are accelerating pharmaceutical research and creating opportunities that were previously beyond reach.

Nevertheless, computational innovation alone cannot produce new medicines. Successful drug development continues to depend on rigorous experimental validation, carefully designed clinical trials, high-quality real-world evidence, and robust regulatory oversight. AI should therefore be regarded as a tool that strengthens scientific investigation rather than replacing the scientific method.

The coming decade is unlikely to be defined by autonomous drug discovery. Instead, it will be characterized by increasingly effective partnerships between artificial intelligence and human expertise. Researchers will continue to formulate biological questions, interpret evidence, and make clinical judgments, while AI will enhance their ability to analyze complexity and generate new therapeutic hypotheses.

Ultimately, the true impact of artificial intelligence will not be determined by how intelligently machines perform, but by how wisely the scientific community chooses to use them. If integrated responsibly, AI has the potential to make drug discovery faster, more precise, and more responsive to unmet medical needs—bringing meaningful benefits to both science and society.

Declarations

Acknowledgements: The author gratefully acknowledges the contributions of researchers, clinicians, computational scientists, and regulatory experts whose work has advanced the application of artificial intelligence in pharmaceutical sciences. Their collective efforts continue to shape a more efficient, evidence-based, and patient-centered approach to drug discovery.

Funding: The author received no specific funding for the preparation of this editorial.

Conflicts of Interest: The author declares that there are no conflicts of interest related to this work.

Author Contributions: Mohsen Zabihi conceived the editorial, reviewed the literature, interpreted the evidence, and wrote the manuscript. The author approved the final version for publication.

Ethics Statement: Ethics approval was not required because this article is an editorial based exclusively on published literature.

References

1.Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493–500.

2.Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. nature. 2021;596(7873):583–9.

3.Zhavoronkov A, Vanhaelen Q, Oprea TI. Will artificial intelligence for drug discovery impact clinical pharmacology? Clinical Pharmacology & Therapeutics. 2020;107(4):780–5.

4.Martin O. Artificial intelligence in drug discovery and development. Advanced Sciences. 2021;3(2):1–10.

5.Ljubimov VA, Sun T, Wang J, Li L, Wang PZ, Ljubimov AV, et al. Blood-Brain Barrier Crossing Biopolymer Activates Immunity in Primary Brain Lymphoma by Targeting c-Myc and α-PD-1: Artificial Intelligence Analysis. Journal of controlled release: official journal of the Controlled Release Society. 2025;381:113611.

6.Sung JJ. Artificial intelligence and the future of medicine. Artificial intelligence in medicine: Elsevier; 2024. p. 1–12.

7.Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, et al. Exploiting machine learning for end-to-end drug discovery and development. Nature materials. 2019;18(5):435–41.

8.Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702. e13.

9.Walters WP, Murcko M. Assessing the impact of generative AI on medicinal chemistry. Nature biotechnology. 2020;38(2):143–5.

10.Müller AT, Hierl M, Heer D, Westwood P, Hartz P, Wörsdörfer B, et al. Machine Learning-Assisted Iterative Screening for Efficient Detection of Drug Discovery Starting Points. Journal of Medicinal Chemistry. 2025;68(14):14806–17.

11.Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nature reviews Drug discovery. 2019;18(6):463–77.

12.Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447–53.

13.Rajkomar A, Dean J, Kohane I. Machine learning in medicine. New England Journal of Medicine. 2019;380(14):1347–58.

14.Rudin C. Why black box machine learning should be avoided for high-stakes decisions, in brief. Nature Reviews Methods Primers. 2022;2(1):81.

15.Corsini NS, Knoblich JA. Human organoids: New strategies and methods for analyzing human development and disease. Cell. 2022;185(15):2756–69.

16.Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends in pharmacological sciences. 2019;40(8):577–91.

17.Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. Jama. 2018;320(9):867–8.

18.Nagel E, Roman YM. The role of real-world data and real-world evidence in advancing regulatory science and targeted therapeutics: a narrative review from the United States perspective. Personalized Medicine. 2026;23(2):123–30.

19.Correia PD, Cordo' V, Blanquie O, Tognana E, Balourdas D-I, Ziogas C, et al. Horizon scanning at EMA: preparing for the medicines of the future. Frontiers in Medicine. 2026;13:1800213.

20.Saini M, Kc G, Williams AJ, Coplan PM, Gressler LE. Regulatory challenges and opportunities: A review of US food and drug Administration-Approved artificial intelligence and machine Learning-Enabled cardiovascular devices. Therapeutic Innovation & Regulatory Science. 2026;60(2):393–422.

21.Wang Y, Song Y, Wang Y, YU L, Wang J. Ethics and governance of artificial intelligence for health: guidance on large multi-modal models. Chinese Medical Ethics. 2024:1001–22.

22.Ishtyaq Mahmud M, Banerjee T. Artificial Intelligence in genomics: a comprehensive survey of methods, resources, challenges, and prospects. Briefings in Bioinformatics. 2026;27(3):bbag229.

23.Rieke N, Hancox J, Li W, Milletari F, Roth HR, Albarqouni S, et al. The future of digital health with federated learning. NPJ digital medicine. 2020;3(1):119.

24.Abedalrhman K, Alzaydi A. Digital Innovations in Healthcare: Harnessing Artificial Intelligence, IoT, and Big Data Analytics for Personalized Medicine and Improved Patient Outcomes-Insights from the Syrian Healthcare Sector. IoT, and Big Data Analytics for Personalized Medicine and Improved Patient Outcomes-Insights from the Syrian Healthcare Sector (May 21, 2025). 2025.

25.Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nature reviews Drug discovery. 2019;18(1):41–58.

  DOI: https://doi.org/10.18502/aptj.v6i1.?????